Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Clinical trial NCT01541709 · UNKNOWN
Trial details
- NCT number
- NCT01541709
- Sponsor
- Asan Medical Center
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-01
- Primary completion
- 2024-12-31
- Enrollment
- 23
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.